Psychiatry

Schizophrenia experts discuss the stigma and misconceptions surrounding schizophrenia as well as current treatment options.

A study found children and young adults with cerebral palsy have more anxiety and less depression than those with a chronic condition or who are typically developed.

A study shows it is safer for nursing home residents on CYP2D6 opioids to take CYP2D6-neutral antidepressants than CYP2D6-inhibiting antidepressants.

Johnson & Johnson submits a supplemental New Drug Application to the FDA for the approval of esketamine as a monotherapy for adults with treatment-resistant depression.

A new study found individuals with depression and anxiety have a high prevalence of medical debt.

A new study confirms GLP-1RAs do not increase the risk for suicidal thoughts or behaviors, aligning with the FDA findings.

After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.

Dunlop discusses what the next steps for MDMA-assisted therapy would be if approved.

Dunlop provided his opinions on the committee’s comments regarding functional unblinding and cardiovascular implicative risks when it comes to studying MDMA.

HCPLive spoke with Joshua M. Cohen, MD, MPH, to discuss a post-hoc analysis of a phase 3 study that showed buprenorphine may be effective at reducing fentanyl use.

Family physician Scuderi shares how he helps patients manage PTSD symptoms ahead of Fourth of July fireworks.

This month in review captures the top FDA updates, including the first FDA Advisory Committee meeting to discuss the NDA for a psychedelic-assisted therapy.

FDA accepts a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, with a PDUFA date of February 8, 2025.

The study APEX-002-B01-02 will evaluate how APEX-52, a microdose psilocybin, can impact safe driving.

A phase 3 trial shows lumateperone as adjunctive therapy with antidepressants significantly reduces depression symptoms in patients with major depressive disorder.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Follow HCPLive's coverage of the full-day FDA committee meeting regarding Lykos Therapeutics' application for MDMA-assisted therapy as a novel treatment for patients with PTSD.

Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.

Emerson previews the highly anticipated FDA advisory committee this week, and Lykos' plans for rolling out MDMA-assisted therapy in the event it is approved to treat PTSD.

New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.

A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.

Van der Kolk discusses the long-term outlook of MDMA in patients with PTSD and what further outcomes he'd like to see explored in the space.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

At APA 2024, psychiatry experts shared their message to their colleagues for Mental Health Awareness Month.

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.